Navigation Links
Lilly Reports First-Quarter 2013 Results
Date:4/24/2013

I program for systemic lupus erythematosus is ongoing and will continue as planned.
  • The company initiated a significant reduction in its U.S. Bio-Medicines sales force to adapt to changing customer requirements, evolutions in the U.S. health care environment and the upcoming loss of exclusivity for Cymbalta and Evista. Substantially all of the severance costs associated with this action were recognized in the fourth quarter of 2012. The company will also implement a small increase in its diabetes sales force to prepare for the planned launches of late-stage pipeline products. 
  • The commercial rights to exenatide outside of the U.S. were transferred to Amylin Pharmaceuticals.
  • The company agreed to end its U.S. co-promotion of Livalo® and return the rights back to its partner, Kowa Pharmaceuticals America, Inc.
  • The Elanco animal health business announced that it will invest approximately $100 million USD to purchase a minority equity stake in China Animal Healthcare Ltd., one of the leading players in the animal health industry in the People's Republic of China. The parties have also agreed to a framework to allow for future commercial collaboration activities.
  • The company completed its previously-announced $1.5 billion share repurchase program.
  • First-Quarter Reported Results
    In the first quarter of 2013, worldwide total revenue was $5.602 billion, which was flat compared with the first quarter of 2012. An increase of 4 percent due to higher prices was offset by decreases of 3 percent due to lower volume and 1 percent due to the unfavorable impact of foreign exchange rates. The decrease in volume was driven primarily by the loss of patent exclusivity for Zyprexa® in most major markets, partially offset by volume gains for certain other products. Total revenue in the U.S. increased 2 percent to $3.137 billion due primarily to increased prices, partially offset by lower volu
    '/>"/>

    SOURCE Eli Lilly and Company
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. DiversityInc Names Lilly a Top Company for Diversity
    2. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
    3. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
    4. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
    5. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
    6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
    7. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
    8. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
    9. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
    10. Lilly Diabetes Launches 8th Annual Diabetes Summer Camp Tour With Olympian Kris Freeman
    11. Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/28/2015)... Lilly and Company (NYSE: LLY ) announced today the ... up to $1.6 billion aggregate principal amount of certain of ... tendered, and did not validly withdraw, their notes on or ... time, on May 27, 2015 (the early tender date), and ... receive the total consideration. The total consideration for each series ...
    (Date:5/28/2015)... and HOUSTON , May 28, 2015 ... EPI) today reported financial results for the second quarter and ... specified otherwise, are expressed in Canadian dollars and in accordance ... Results ESSA recorded a net loss of ... ended March 31, 2015 (Q2-2015), compared to a net loss ...
    (Date:5/28/2015)... Research and Markets ( ... Jain PharmaBiotech,s new report  "RNAi - Technologies, ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... the use of double stranded RNA (dsRNA). ... processed into short 21-23 nucleotide RNAs termed ...
    Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
    ... ( www.curemark.com ), a drug research and development company focused ... & Renshaw Annual Global Investment Conference held September 12-15 in ... 5,000 investors and other attendees.   "Curemark was ... present at the conference, which included a full roster of ...
    ... OmniComm Systems, Inc. (OTC Bulletin Board: ... and services announced that it will be hosting the ... Beach Resort in Fort Lauderdale, Florida from November 03-05, ... from participating Life Science organizations. The informal ambiance provides ...
    Cached Medicine Technology:Curemark Presents at the Rodman & Renshaw Annual Global Investment Conference 2OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 2OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 3
    (Date:5/29/2015)... (PRWEB) May 29, 2015 Healthpointe is ... Joint Fluid Therapy (JFT) at their clinics in Orange ... injectable treatment that assists in diminishing pain for patients ... Dr. Stanley Katz and Dr. Neil Katz of Healthpointe. ... sodium hyaluronate (also known as hyaluronic acid) a natural ...
    (Date:5/29/2015)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 29, 2015 ... in the vulvar region and can cause significant physical, ... understands the major life altering disorder of Vulvodynia. The ... exclusion. At Women’s Excellence in Endometriosis, they realize that ... If a patient is experiencing any of these symptoms, ...
    (Date:5/29/2015)... The popular all-natural supplement brand, Liporidex, ... Select Program that gives bonuses to members for their ... 100 members per year, lucky members who are selected ... fitness experts at Nuretix Research, and get exclusive benefits ... they attain and maintain their weight loss and fitness ...
    (Date:5/29/2015)... Louisville, KY (PRWEB) May 29, 2015 ... private and government entities to discuss and foster the ... data to improve health. The Conference is hosted by ... government, non-profit, and private organizations to promote and develop ... conference, there are several focused groups to narrow in ...
    (Date:5/29/2015)... External Counterpulsation, also known as EECP ... patients. The Heart Fit Clinic is the first clinic in ... review from patients who are now completing treatment. , ... treatments of ECP treatment and received great results. His ... does the clinic perform this non-surgical treatment for heart disease, ...
    Breaking Medicine News(10 mins):Health News:Healthpointe is Now Offering Supartz Joint Fluid Therapy at their Anaheim Clinic and La Mirada Clinic. 2Health News:Liporidex, a Sports Nutrition Supplement Brand, Is Searching For Members For Their Exclusive L-Style Select Program Which Rewards Members For Their Achievements 2Health News:RowdMap, Inc. Speaks on Government Health Data and Applications for Transparency, No Value Care, and Pay-for-Value Risk Arrangements at Health Datapalooza 2Health News:RowdMap, Inc. Speaks on Government Health Data and Applications for Transparency, No Value Care, and Pay-for-Value Risk Arrangements at Health Datapalooza 3Health News:External Counterpulsation at Heart Fit Clinic Receives Raving Review 2
    ... (MGH) researchers have identified a new molecular pathway that ... This early-stage kidney disease affects 100 million people around ... the kidneys filtering structures. Blocking this pathway could ... slow the process of kidney failure. The research ...
    ... impact on behavior, studies show , , WEDNESDAY, Dec. 19 (HealthDay ... trillion cells, looking for perhaps only one or a handful ... of new studies says. , The research, conducted with rodents ... , could rewrite the textbooks on just how important individual ...
    ... a way to use a firefly gene to let them ... against some forms of cancer and its serious complication. ... and leukemia, a form of cancer where it is particularly ... prognosis is generally poor. There is now no widely effective ...
    ... Helping Latino Nonprofits and Families With Cash,Donation. Photo ... Latino with,HIV., WASHINGTON, Dec. 19 The ... This holiday season, MAYA is giving $10,000 to ... the Latino community.,MAYA will also donate cash to ...
    ... Health Net of California See Big Increases in ... Surveyor from HealthLeaders-InterStudy Reveals ... NASHVILLE, Tenn., Dec. 19 HealthLeaders-InterStudy, the,leading ... managed,care enrollment from January 2007 to July 2007 ...
    ... volunteer John,Cleland has run four marathons, but the race ... Diagnosed with the disease as a college,undergraduate, Cleland underwent ... punishing rounds of chemotherapy followed. But when,Cleland,s cancer spread ... Then Cleland,s doctor offered one small ray of ...
    Cached Medicine News:Health News:Receptor protein appears to be key in breakdown of kidney filtration 2Health News:Receptor protein appears to be key in breakdown of kidney filtration 3Health News:Brain Cells More Powerful Than You Think 2Health News:Brain Cells More Powerful Than You Think 3Health News:Brain Cells More Powerful Than You Think 4Health News:Firefly genes allow testing of new therapy against lymphoma 2Health News:Firefly genes allow testing of new therapy against lymphoma 3Health News:HIV/AIDS Rate Increases in DC Area Latino Population, Community Lacks Resources 2Health News:Boosts in Managed Care Enrollment Seen Across The Board 2Health News:Boosts in Managed Care Enrollment Seen Across The Board 3Health News:New Book Looks at Clinical Research from the Patient's Point of View 2Health News:New Book Looks at Clinical Research from the Patient's Point of View 3
    ... vascular tests for assessing peripheral vascular disease. With the Portable ABI Kit, you get the basic equipment ... ... ... The ankle-arm pressure index (also known as the Ankle/Brachial ...
    ... Clinitek Microalbumin Strips provide albumin, creatinine ... The Clinitek Microalbumin product is useful to ... or hypertension in order to detect early ... elevation of the urinary albumin excretion rate, ...
    ... today's busy physician's office environment, ... contribute to timing errors and ... strips are read visually. Studies ... is performed with an instrument, ...
    ... Ultra device consists of a non-compliant balloon ... mounted longitudinally on its outer surface. When ... the atherotomes score the plaque, creating initiation ... to as Atherotomy, allows dilatation of the ...
    Medicine Products: